Olivier Brandicourt
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Transaction History
| PCVX | ▲ Buy | Grant | 2,194 | $0 | 6/15/2026 | View on chart |
| ONC | ▲ Buy | Grant | 18,980 | $0 | 6/11/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 671 | $0 | 5/20/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 1,357 | $0 | 1/15/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 1,148 | $0 | 6/12/2025 | View on chart |
| ONC | ▲ Buy | Grant | 10,985 | $0 | 5/21/2025 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| ONC | ▲ Buy | Grant | 16,341 | $0 | 6/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.